Navigation Links
Governor O'Malley Announces State Grants Available For Maryland Bio Companies

BALTIMORE, Aug. 24 /PRNewswire-USNewswire/ -- Governor Martin O'Malley announced today that State grants are available in Fiscal Year 2011 through the Maryland Biotechnology Center to assist in commercializing promising research, encouraging bio companies to collaborate with academic institutions and expanding biotechnology resources.  The Governor also announced that seven Maryland bio companies and universities received $1.3 million in FY 2010 grants, which was the first year of funding.

"Biotechnology continues to be a key driver of Maryland's economy," said Governor O'Malley. "The high quality of the biotechnology projects supported by these awards, as well as their link to a number of Maryland institutions of higher learning, demonstrates Maryland's significant potential to commercialize our unparalleled academic research."

Applications for the Biotechnology Commercialization Awards and the Translational Research Awards must be submitted by September 15th to the Maryland Biotechnology Center (MBC), a part of the Maryland Department of Business and Economic Development (DBED), at  These grants complement funding available through TEDCO's Maryland Technology Transfer and Commercialization Fund, the University of Maryland's Maryland Industrial Partnerships Program and DBED's Maryland Venture Fund programs.

In Fiscal Year 2010, the Biotechnology Commercialization Awards were made to three biotechnology companies to assist them in commercializing a product or service.  College Park-based Zymetis, received a $200,000 grant to advance their work in converting whey to fuel; Fyodor, based in Baltimore's BioPark, received $200,000 for the commercialization of their flagship product, the Urine Malaria Test; and InfraTrac, located at the Silver Spring Innovation Center, received $100,000 to grow their counterfeit drug monitoring product.

The Translational Research Awards, which are given to help commercialize basic science research and encourage bio companies to collaborate with academic institutions, were presented to Baltimore-based Gliknik Inc., in partnership with the University of Maryland, Baltimore and Dr. James S. Gammie of the University of Maryland Medical Center.  Each has received a $200,000 award. Gliknik will use its award to support development of a drug that aids in organ transplants, with a significant portion of the funding going to transplant researchers at the University of Maryland. Dr. Gammie will use the funding to develop surgical tools that will assist in repairing the heart's mitral valve through a minimally invasive procedure.

The Shared Resource Grants, totaling $400,000, were awarded to two University of Maryland programs that provide specialized services to local bio companies. The Maryland Technology Enterprise Institute (MTECH) Biotechnology Research and Education program received $200,000 to expand its operations into a new facility at Shady Grove.  A second $200,000 grant was awarded to the Department of Chemistry and Biochemistry at the University of Maryland, Baltimore County for the purchase of new equipment, specifically a state-of-the-art mass spectrometer.  

SOURCE Maryland Department of Business and Economic Development
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Howard J. Leonhardt Announces Candidacy for Governor of California
2. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
3. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
4. The Biotechnology Industry Organization Honors Georgia Governor Sonny Perdue as Governor of the Year
5. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
6. Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey
7. Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO)
8. 3SBio Inc. Announces Unaudited Second Quarter Results
9. SeqWright Announces the Addition of Illumina HiSeq 2000 to its Next Generation Sequencing Capabilities
10. Spherix Announces Second Quarter 2010 Financial Results
11. Ingenuity Systems Announces Toxicogenomics Best Practices White Paper
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):